Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati sponsors 571 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 372 completed. 38 of these trials are in Phase 3-4 (later-stage) and 140 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autism Spectrum Disorder, with 13 trials.
Trial Pipeline
571 total, page 11 of 12
Sodium Supplementation and Growth in Very Low Birth Weight Infants
NCT01795638
Linguistic Characteristics of Suicidal Patients in the Emergency Department
NCT01594138
Development of PK/PD Model for Individualized Propofol Dosing
NCT00948597
Effectiveness of Monovalent Rotavirus Vaccine (RV1)
NCT01871038
Disseminating a Model Intervention to Promote Improved Attention-deficit Hyperactivity Disorder (ADHD) Care in the Community
NCT01056016
Pharmacogenetic Morphine Spine Study
NCT01839461
Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea
NCT01344759
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
NCT00792233
Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes
NCT01034527
Launch II: A Pilot Randomized Control Trial of a Clinic and Clinic Plus Home Intervention for Preschool Obesity
NCT01419951
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
NCT00890786
Screening Patients With Sickle Cell Disease for Kidney Damage
NCT02239016
An Assessment of Voluntary Adolescent Mental Health Screening and Referral in a Children's Hospital Emergency Department
NCT00750412
Two Anesthetic Techniques in Magnetic Resonance Imaging (MRI)
NCT00894751
Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
NCT00792766
CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT00783783
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
NCT00786669
Pharmacokinetics of Levetiracetam (Keppra) in Neonates
NCT01261416
Interacting Together Everyday: Recovery After Childhood Traumatic Brain Injury (TBI) "I-InTERACT
NCT01056146
Tuberous Sclerosis Complex Natural History Study: Renal Manifestations
NCT00598455
Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants
NCT00610688
Behavioral Rx & Nutrition in Pediatric Chronic Disease
NCT01018121
Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD
NCT00631280
Alternate Day Micafungin: A PK Study in Pediatric Patients
NCT00842504
Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial
NCT03007134
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100
NCT00479115
Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine
NCT00671931
Montelukast in Very Low Birthweight Infants
NCT00492102
Internet-Based Treatment for Children With Traumatic Brain Injuries & Their Families: Counselor Assisted Problem Solving
NCT00409448
Role of Placenta Growth Factor in Sickle Acute Chest Syndrome
NCT00448370
Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients
NCT00433953
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
NCT00411619
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
NCT00530270
A Research Study for Children About Heart Changes and Obstructive Sleep Apnea (OSA)
NCT01837459
Treatment of Depression in Mothers in Home Visitation
NCT01221701
Environmental Exposures, Genetics, and Exhaled Nitric Oxide in Pediatric Asthma
NCT00395096
Testing Four Feeding Approaches to Oral Feeding in Preterm Infants
NCT02024828
Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)
NCT01238822
Attention Deficit Disorder Medication Response Study
NCT01727414
Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation
NCT00410150
GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis
NCT01589523
Behavioral & Nutritional Treatment to Help CF Preschoolers Grow
NCT00241969
PK-PD Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients
NCT00281619
Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy
NCT00272870
Teen Online Problem Solving (TOPS) - An Online Intervention Following TBI
NCT00409058
Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia
NCT00965666
Intralumenal Effects on Cholesterol Absorption/Synthesis
NCT00328211
Adolescent Gastric By-pass and Diabetic Precursors
NCT00360373
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
NCT00457964
CV Disease in Adolescents With Type 2 Diabetes
NCT00114998
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 86 |
| Phase 2 | 54 |
| Phase 3 | 15 |
| Phase 4 | 23 |
Therapeutic Areas
What the Pipeline for Children's Hospital Medical Center, Cincinnati Shows
According to the ClinicalTrials.gov registry, Children's Hospital Medical Center, Cincinnati is linked to 571 US clinical trials across every stage of research activity. Of those, 106 studies are currently recruiting, about 19% of the sponsor's indexed portfolio, and 372 are already marked complete, representing roughly 65% of the total.
The phase mix for Children's Hospital Medical Center, Cincinnati reports 38 late-stage studies (Phase 3 and Phase 4 combined) and 140 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Children's Hospital Medical Center, Cincinnati is Autism Spectrum Disorder with 13 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.